301. Macular dystrophy Clinical trials / Disease details
Clinical trials : 45 / Drugs : 46 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05244304 (ClinicalTrials.gov) | March 2022 | 20/1/2022 | Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1 | Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects | Stargardt Disease 1 | Drug: Tinlarebant;Drug: Placebo | Belite Bio, Inc | NULL | Not yet recruiting | 12 Years | 18 Years | All | 60 | Phase 3 | United States;Australia;Hong Kong;Taiwan;United Kingdom;France;Germany;Switzerland |
| 2 | NCT05266014 (ClinicalTrials.gov) | March 12, 2021 | 26/1/2022 | This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease | Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease | Stargardt Disease | Drug: tinlarebant | RBP4 Pty Ltd | Belite Bio, Inc | Active, not recruiting | 12 Years | 18 Years | All | 13 | Phase 1/Phase 2 | Australia;Taiwan |